1 / 6

SMASH-VT Trial

Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial. SMASH-VT Trial. Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Vivek Reddy. SMASH-VT Trial: Background.

fawzi
Download Presentation

SMASH-VT Trial

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial SMASH-VT Trial Presented at The Heart Rhythm Society Meeting May 2006 Presented by Dr. Vivek Reddy

  2. SMASH-VT Trial: Background • The goal of the trial was to evaluate treatment with ICD implantation with catheter ablation compared with ICD alone among post myocardial infarction (MI) patients with sustained ventricular tachycardia (VT)/ ventricular fibrillation (VF) Presented at HRS 2006

  3. SMASH-VT Trial: Study Design 126 patients not using class l or lll antiarrhythmic drugs, prior MI, and either VF arrest, unstable VT, or prior ICD and single appropriate shock Randomized. 13% female, mean age 66 years, mean follow-up 2 years 71% NYHA Class ll, 18% NYHA Class lll, Mean EF 31.7% 18% had VF arrest, 52% had unstable VT, 21% had syncope and inducible VT and 9% had prior ICD and single appropriate shock, 96% received beta-blockers and 91% received ACE-inhibitors, index MI was anterior in 41% of patients and 67% had prior revascularization ICD implantation with substrate-based catheter ablation n=62 ICD alone n=64 • Primary Endpoint: Appropriate ICD therapies • Ablation was performed with electroanatomic mapping to delineate the endocardial infarct margins • The radiofrequency ablation catheter used either a standard 4mm (n=10) or an irrigated 3.5 mm tip (n=52) Presented at HRS 2006

  4. SMASH-VT Trial: Primary Endpoint Primary endpoint of appropriate ICD therapy (%) p<0.05 Incidence of appropriate ICD shock (%) p<0.05 • The primary endpoint of appropriate ICD therapy occurred less frequently in the ablation group compared with the control group (15% vs. 33% p=<0.05), as did appropriate ICD shock (10% vs. 33%, p=<0.05). Presented at HRS 2006

  5. SMASH-VT Trial: Adverse Events Mortality among both patient groups (%) p=0.073 • Mortality occurred in 7% of the ablation group and 17% of the control group (p=0.073). • Among the adverse events in the ablation group, there was one pericardial effusion without tamponade, one deep vein thrombosis, and one CHF exacerbation. Presented at HRS 2006

  6. SMASH-VT Trial: Summary • Among post-MI patients with sustained VT/VF, ICD implantation with substrate-based catheter ablation was associated with a reduction in appropriate ICD therapy through two years compared with ICD therapy alone. • The present trial suggests that the procedure can also be effective in reducing ICD shocks in the post-MI setting, although it should be noted that the procedure is difficult to perform and extremely technical, so use for prophylactic therapy should be undertaken with caution and only in experienced centers. Presented at HRS 2006

More Related